EyePoint Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

EyePoint Pharmaceuticals CEO'su Jay Duker, Jan2023 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 2.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.1% maaş ve 78.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.091% ine doğrudan sahiptir ve bu hisseler € 667.24K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 3.3 yıldır.

Anahtar bilgiler

Jay Duker

İcra Kurulu Başkanı

US$2.9m

Toplam tazminat

CEO maaş yüzdesi	21.1%
CEO görev süresi	1.8yrs
CEO sahipliği	0.09%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jay Duker'un ücretlendirmesi EyePoint Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$87m
Mar 31 2024	n/a	n/a	-US$79m
Dec 31 2023	US$3m	US$614k	-US$71m
Sep 30 2023	n/a	n/a	-US$100m
Jun 30 2023	n/a	n/a	-US$106m
Mar 31 2023	n/a	n/a	-US$102m
Dec 31 2022	US$2m	US$515k	-US$102m
Sep 30 2022	n/a	n/a	-US$78m
Jun 30 2022	n/a	n/a	-US$77m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$3m	US$269k	-US$58m
Sep 30 2021	n/a	n/a	-US$54m
Jun 30 2021	n/a	n/a	-US$42m
Mar 31 2021	n/a	n/a	-US$44m
Dec 31 2020	US$53k	n/a	-US$45m
Sep 30 2020	n/a	n/a	-US$40m
Jun 30 2020	n/a	n/a	-US$52m
Mar 31 2020	n/a	n/a	-US$51m
Dec 31 2019	US$80k	n/a	-US$57m
Sep 30 2019	n/a	n/a	-US$58m
Jun 30 2019	n/a	n/a	-US$75m
Mar 31 2019	n/a	n/a	-US$98m
Dec 31 2018	US$27k	n/a	-US$86m

Tazminat ve Piyasa: Jay 'nin toplam tazminatı ($USD 2.92M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.45M ).

Tazminat ve Kazançlar: Jay şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jay Duker (65 yo)

1.8yrs

Görev süresi

US$2,915,146

Tazminat

Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jay Duker	President	1.8yrs	US$2.92m	0.091% € 667.2k
George Elston	Executive VP & CFO	5yrs	US$1.78m	0.072% € 523.4k
John Landis	Interim Head of R&D and Director	less than a year	US$161.67k	0.017% € 125.7k
Michael Maciocio	Senior Vice President of Manufacturing & Operations	1.3yrs	Veri yok	Veri yok
Ron Honig	Chief Legal Officer & Company Secretary	6yrs	Veri yok	Veri yok
Jennifer Leonard	Chief People Officer & Senior VP of IT	5.8yrs	Veri yok	Veri yok
David Jones	Senior VP & Chief Commercial Officer	5.4yrs	US$1.46m	0% € 0
Michael Pine	Chief Business Officer	1.1yrs	US$1.61m	0.021% € 150.6k
Isabelle Lefebvre	Chief Regulatory Officer	2.7yrs	Veri yok	Veri yok
Marcia Sellos-Moura	Senior VP and Head of Development & Program Management	1.3yrs	Veri yok	Veri yok
Ramiro Ribeiro	Chief Medical Officer	less than a year	Veri yok	Veri yok
Anna Kluczewska	CEO of AION Diagnostics Ltd	no data	US$225.94k	Veri yok

1.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: PV3B 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jay Duker	President	1.3yrs	US$2.92m	0.091% € 667.2k
John Landis	Interim Head of R&D and Director	6.1yrs	US$161.67k	0.017% € 125.7k
Anna Kluczewska	CEO of AION Diagnostics Ltd	no data	US$225.94k	Veri yok
Goran Ando	Independent Non-Executive Chairman	6.4yrs	US$214.78k	0.020% € 145.0k
Wendy DiCicco	Independent Director	5.3yrs	US$171.67k	0.015% € 109.9k
Nancy Lurker	Vice Chair	8.2yrs	US$3.74m	0.34% € 2.5m
Carl Regillo	Co- Chairman of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Glenn Jaffe	Member of Executive Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Karen Zaderej	Independent Director	2.3yrs	US$149.17k	0.025% € 181.9k
Charles Wykoff	Co-Chair of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Rishi Singh	Member of Executive Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Sophie Bakri	Member of Executive Scientific Advisory Board	3.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PV3B 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

EyePoint Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

EyePoint Pharmaceuticals, Inc. Announces Board Changes

Insider recently bought €90k worth of stock

High number of new directors

EyePoint Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board

EyePoint Pharmaceuticals, Inc. Announces Management Changes

Recent updates

New major risk - Revenue and earnings growth

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

EyePoint Pharmaceuticals, Inc. Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema

Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of Durasert for the Treatment of Wet Age-Related Macular Degeneration

Now 22% undervalued

EyePoint Pharmaceuticals, Inc. Announces Board Changes

Insider recently bought €90k worth of stock

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Second quarter 2024 earnings released: US$0.58 loss per share (vs US$0.61 loss in 2Q 2023)

New major risk - Revenue and earnings growth

New minor risk - Insider selling

EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.56 loss in 1Q 2023)

High number of new directors

New major risk - Shareholder dilution

EyePoint Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board

Full year 2023 earnings released: US$1.82 loss per share (vs US$2.74 loss in FY 2022)

EyePoint Pharmaceuticals, Inc. Announces Management Changes

EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Executive Vice-Chairman recently sold €802k worth of stock

EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema

Executive Vice-Chairman recently sold €384k worth of stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.49 loss in 3Q 2022)

EyePoint Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

EyePoint Pharmaceuticals, Inc. Announces Executive Changes

EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.52 loss in 2Q 2022)

EyePoint Pharmaceuticals, Inc. Announces Interim Masked Safety Data and Patient Baseline Characteristics for EYP-1901

EyePoint Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Eyepoint Pharmaceuticals Completes Enrollment in Phase 2 Pavia Clinical Trial of Eyp-1901 in Non-Proliferative Diabetic Retinopathy

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

Now 20% undervalued

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.56 loss in 1Q 2022)

Full year 2022 earnings released: US$2.74 loss per share (vs US$2.03 loss in FY 2021)

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

High number of new directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$0.58 loss in 3Q 2021)

EyePoint Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 02, 2022

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

Second quarter 2022 earnings released: US$0.52 loss per share (vs US$0.35 loss in 2Q 2021)

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

EyePoint Pharmaceuticals, Inc. Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. Appoints Karen Zaderej to Board of Directors

EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.50 loss in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

EyePoint Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Third quarter 2021 earnings released: US$0.58 loss per share (vs US$0.30 loss in 3Q 2020)

EyePoint Pharmaceuticals, Inc. to Present Data At the American Academy of Ophthalmology 2021 Annual Meeting